New methods to develop drugs that target tau proteins in neurodegenerative diseases
Official title: Novel Approaches for Tau PROTAC Drug Discovery
Funded at Lifesensors, INC. · NIH-10888256 · Data updated 2026-11-12
This study is exploring new medications that aim to help people with Alzheimer's and frontotemporal dementia by targeting and removing harmful tau proteins in the brain, which could lead to better treatment options for those affected by these conditions.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Lifesensors, INC. NIH-funded |
| Lab location | 1 site (Malvern, United States) |
| Project start | September 15, 2020 |
| Project end | March 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,245,086 |
| NIH project number | 5R44AG066271-03 |
| Project ID | NIH-10888256 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Alzheimer's disease, frontotemporal dementia, or other tau-related neurodegenerative disorders.
✕Less likely to help
Patients with neurodegenerative diseases not associated with tau protein accumulation may not benefit from this research.
What this research studies
This research focuses on developing innovative drug therapies that target tau proteins, which are implicated in neurodegenerative diseases like Alzheimer's and frontotemporal dementia. The approach utilizes PROteolysis TArgeting Chimeras (PROTACs), which are designed to selectively degrade harmful tau protein aggregates in the brain. By binding to both the tau protein and a specific ligase, these drugs aim to promote the removal of toxic protein forms that contribute to cell death. This could potentially lead to new treatment options for patients suffering from these debilitating conditions.
Why it matters
Potential benefit: If successful, this research could lead to effective treatments that slow down or halt the progression of neurodegenerative diseases associated with tau protein accumulation.
How similar studies have gone: While the use of PROTACs is a relatively novel approach, preliminary research has shown promise in targeting other proteins, suggesting potential for success in this area as well.
Where this research is happening
-
Lifesensors, INC.
Malvern, United States Active
Researchers
- Principal investigator: Butt, Tauseef R. — Lifesensors, INC.
- Study coordinator: Butt, Tauseef R.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.